Learn how treatment of NSCLC with checkpoint inhibitors will affect your clinical outlook.
This activity is intended for pulmonologists, ID/HIV specialists, and pathologists who treat patients with lung cancer.
The goal of this activity is to provide pulmonologists perspectives on how immune checkpoint inhibitors may alter the diagnostic algorithm in individuals with suspected lung cancer.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Aug. 31, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Interpret clinical evidence related to the use of immune checkpoint inhibitors in patients with lung cancer
- Identify how the incorporation of immune checkpoint inhibitors in patients with lung cancer may alter diagnostic strategies